Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease

NCT06858397 is registered in ClinicalTrials.gov with GC Biopharma Corp as lead sponsor.

NCT NCT06858397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease
Lead sponsor
GC Biopharma Corp
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2025
Completion date
August 30, 2028
Enrollment
18 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disesase